Express News | Teva : HSBC Raises Target Price to $23 From $20
Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Argus Research Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $22
Express News | Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $22
Teva Pharmaceutical Indus Analyst Ratings
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
Express News | Teva : Barclays Raises Target Price to $22 From $21
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
Express News | Teva : Piper Sandler Raises Target Price to $23 From $20
Express News | Teva : JP Morgan Raises Target Price to $16 From $15
Teva Pharmaceutical Industries Options Spot-On: On July 31st, 83,206 Contracts Were Traded, With 711.61K Open Interest
10-Q: Q2 2024 Earnings Report
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
Medincell's Partner Teva Provides Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY Commercial Progress
Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?